Scarica l'app Stockscreener
7.49
4.59%
-0.36
Dopo l'orario di chiusura:
7.49
Precedente Chiudi:
$7.85
Aprire:
$7.71
Volume 24 ore:
431.81K
Relative Volume:
1.04
Capitalizzazione di mercato:
$444.29M
Reddito:
$27.46M
Utile/perdita netta:
$-46.05M
Rapporto P/E:
-5.8062
EPS:
-1.29
Flusso di cassa netto:
$-33.83M
1 W Prestazione:
-8.77%
1M Prestazione:
-6.49%
6M Prestazione:
+7.93%
1 anno Prestazione:
+29.14%
Intervallo 1D:
$7.45
$7.745
Intervallo di 1 settimana:
$7.45
$8.22
Portata 52W:
$4.20
$9.76
Zevra Therapeutics Inc Stock (ZVRA) Company Profile
Nome
Zevra Therapeutics Inc
Settore
Industria
Telefono
(321) 939-3416
Indirizzo
1180 CELEBRATION BOULEVARD, SUITE 103, CELEBRATION
Confronta ZVRA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ZVRA
Zevra Therapeutics Inc
|
7.49 | 444.29M | 27.46M | -46.05M | -33.83M | -1.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Zevra Therapeutics Inc Stock (ZVRA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-08 | Ripresa | Cantor Fitzgerald | Overweight |
| 2024-10-07 | Iniziato | Guggenheim | Buy |
| 2024-09-24 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-09-24 | Reiterato | Maxim Group | Buy |
| 2024-04-02 | Reiterato | Maxim Group | Buy |
| 2024-03-12 | Iniziato | William Blair | Outperform |
| 2023-03-17 | Iniziato | Maxim Group | Buy |
Mostra tutto
Zevra Therapeutics Inc Borsa (ZVRA) Ultime notizie
Zevra therapeutics director Corey Watton buys $2,351 in stock - Investing.com India
Zevra Therapeutics Asks Shareholders to Reject Director Nominees by Activist Investor - MarketScreener
Zevra Therapeutics Files Preliminary Proxy - The Manila Times
Proxy Fight Erupts at Zevra: Former CEO Challenges $150M Cash-Rich Biotech - Stock Titan
Trend Tracker for (ZVRA) - news.stocktradersdaily.com
John Bode Bought 33% More Shares In Zevra Therapeutics - simplywall.st
Zevra Therapeutics Independent Director Acquires 33% More Stock - Yahoo Finance
Insider Buying: John Bode Acquires Additional Shares of Zevra Th - GuruFocus
Zevra therapeutics director Bode acquires $79,624 in stock By Investing.com - Investing.com Canada
Zevra therapeutics director Bode acquires $79,624 in stock - Investing.com
ZEVRA THERAPEUTICS Director John B Bode Acquires 10,000 Shares - TradingView
Woodline Partners LP's Strategic Acquisition of Zevra Therapeuti - GuruFocus.com
Zevra Therapeutics’ SWOT analysis: stock poised for growth amid rare disease focus - Investing.com Australia
Zevra Therapeutics’ SWOT analysis: stock poised for growth amid rare disease focus By Investing.com - Investing.com South Africa
HC Wainwright Predicts Lower Earnings for Zevra Therapeutics - Defense World
(ZVRA) On The My Stocks Page - news.stocktradersdaily.com
Guggenheim Forecasts Strong Price Appreciation for Zevra Therapeutics (NASDAQ:ZVRA) Stock - Defense World
Zevra Therapeutics (NASDAQ:ZVRA) Earns Overweight Rating from Cantor Fitzgerald - Defense World
Roth Capital Predicts Weaker Earnings for Zevra Therapeutics - Defense World
Zevra Therapeutics (ZVRA) Reports Q4 Loss, Tops Revenue Estimates - MSN
Canaccord raises Zevra Therapeutics target to $25; Keeps Buy rating By Investing.com - Investing.com Australia
Zevra Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings) - Benzinga
Optimistic Buy Rating for Zevra Therapeutics Driven by Miplyffa Launch and Strategic Financial Moves - TipRanks
Canaccord raises Zevra Therapeutics target to $25; Keeps Buy rating - Investing.com India
Zevra Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Zevra Therapeutics’ Earnings Call Highlights Success and Growth - TipRanks
Sector Update: Health Care -March 12, 2025 at 01:43 pm EDT - Marketscreener.com
Cantor Fitzgerald maintains $25 target on Zevra Therapeutics stock - Investing.com
Zevra Therapeutics stock target raised to $18 at JMP - Investing.com India
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q4 2024 Earnings Call Transcript - Insider Monkey
Cantor Fitzgerald maintains $25 target on Zevra Therapeutics stock By Investing.com - Investing.com South Africa
Zevra Therapeutics stock target raised to $18 at JMP By Investing.com - Investing.com South Africa
Zevra Therapeutics Inc (ZVRA) Q4 2024 Earnings Call Highlights: Record Revenue and Strategic ... - Yahoo Finance
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Recommendation of “Buy” by Analysts - Defense World
Earnings call transcript: Zevra Therapeutics Q4 2024 reports wider losses By Investing.com - Investing.com Australia
Zevra Therapeutics Inc (ZVRA) Q4 2024 Earnings Call Highlights: Record Revenue and Strategic Expansion Plans - GuruFocus.com
Zevra Therapeutics: Strong Financial Performance and Strategic Growth Justify Buy Rating - TipRanks
Zevra Therapeutics: Q4 Earnings Snapshot - The Washington Post
Zevra Therapeutics Reports 2024 Financial Results and Strategic Progress - TipRanks
ZEVRA THERAPEUTICS Earnings Results: $ZVRA Reports Quarterly Earnings - Nasdaq
Earnings call transcript: Zevra Therapeutics Q4 2024 reports wider losses - Investing.com
Zevra Therapeutics earnings missed by $0.27, revenue topped estimates - Investing.com Australia
Zevra Therapeutics Q4 Net Loss Widens, Revenue Decreases; Shares Fall After Hours - Marketscreener.com
Zevra Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Zevra Reports Full Year 2024 and Fourth Quarter Financial Results - GlobeNewswire
Zevra Earnings: Q4 Revenue Surges to $12M as MIPLYFFA Launch Gains Traction - StockTitan
Investors Appear Satisfied With Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Prospects - Simply Wall St
Zevra Therapeutics (ZVRA) Expected to Announce Earnings on Tuesday - Defense World
Rhumbline Advisers Has $568,000 Position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World
Zevra Therapeutics Inc Azioni (ZVRA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.05%
1.79%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):